Results 31 to 40 of about 15,012 (140)

Thrombocytosis and the generation of platelet‐derived microparticles in the pathophysiology of sickle cell disease

British Journal of Haematology, Volume 209, Issue 2, Page 420-431, August 2026.
Thrombocytosis is associated with an increased production of platelet‐derived microparticles from activated platelets, which contribute to vaso‐occlusion in sickle cell disease by perpetuating the cycle of inflammation, procoagulant state and endothelial dysfunction.
Giao N. Lê, Anna Dillon, Owen P. Smith, Corrina McMahon   +3 more
wiley   +1 more source

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

British Journal of Pharmacology, Volume 183, Issue 15, Page 4111-4125, August 2026.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden, Loes C. Oskam, Lenny van Bon, Chantal P. Rovers   +3 more
wiley   +1 more source

Pragmatic Clinical Trial of Fostamatinib as Second‐Line Therapy in Adult Patients With Immune Thrombocytopenia and Insufficient Response to Prior Therapy: The Fostamatinib FORTE Trial

eJHaem, Volume 7, Issue 4, August 2026.
Amber Afzal, Robert Kribs, Sumit Sawhney, Mohit Narang, Frances Blevins, Robert Numerof, Francois Di Trapani, Sherry Ladha, Ruchika Goel   +8 more
wiley   +1 more source

Thrombopoietin

Drugs of the Future, 1996
Kenneth Kaushansky, Nancy Lin, Angelika Grossmann, Katherine Sprugel, Ewa Sitnicka, Virginia Broudy   +5 more
  +6 more sources

Temporal Lysophosphatidic Acid Supplementation Enhances Megakaryocyte Differentiation and Platelet Production From Human Hematopoietic Progenitors. [PDF]

Cell Biol Int
Jiamvoraphong N, Lorthongpanich C, Septham P, Klaihmon P, Kheolamai P, Laowtammathron C, Imsoonthornruksa S, Ketudat-Cairns M, Issaragrisil S.   +8 more
europepmc   +1 more source

Romiplostim-N01 for cancer therapy-induced thrombocytopenia: A propensity score-matched cohort study. [PDF]

Medicine (Baltimore)
Yu T, Xiong Z, Su Y, Jian Y, Liu L, Wang Y.   +5 more
europepmc   +1 more source

Real-world use of thrombopoietic agents in treatment-naïve children with severe aplastic anemia: a multicenter retrospective study. [PDF]

Sci Rep
Chazli YE, Abdallah G, Zakaria M, Darwish A, Khalifa G, Hassan T, Elhawary E, Elbahy S, Salama M, Alrawas A, Wali Y, Zeid M.   +11 more
europepmc   +1 more source

Personalized Management of Cytopenias in Chronic Liver Disease: From Pathophysiology to Treatment Strategies. [PDF]

JGH Open
Wang X, Fu S, Zhu X, Zhao Y.
europepmc   +1 more source

Successful Treatment of Evans Syndrome Onset With Zanubrutinib in Combination With Romiplostim During Venetoclax Treatment in a Patient With Chronic Lymphocytic Leukemia: A Case Report. [PDF]

Clin Case Rep
Innao V, Barbagallo APM, Bianco O, Leotta V, Consoli U.   +4 more
europepmc   +1 more source

Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study. [PDF]

Br J Haematol
Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, Pathak P, Feinberg B, Maitland H.   +8 more
europepmc   +1 more source